Answers are grounded in this paper and cite their sources.
Rituximab, an anti-CD20 monoclonal antibody, is generally a safe and well-tolerated drug. Severe acute thrombocytopenia following administration of rituximab is a rare phenomenon, with few previously reported cases in the literature. We report a case of an 84-year old male with a diagnosis of mantle cell lymphoma who suffered severe acute thrombocytopenia following rituximab infusion. A literature review of the previously published cases is also presented.
No takes yet. Share an insight, caveat, or question.
Dhand et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: